Short Insulin Tolerance Test Can Determine the Effects of Thiazolidinediones Treatment in Type 2 Diabetes

다국어 초록 (Multilingual Abstract)

Purpose: The short insulin tolerance test is a simple and reliable method of estimating insulin sensitivity. This study was designed to compare the insulin sensitizing effects of thiazolidinediones (TZDs) on the degree of insulin resistance, determined by a short insulin tolerance test (Kitt) in type 2 diabetic patients. Patients and Methods: Eighty-three subjects (mean age=57.87±10.78) with type 2 diabetes mellitus were enrolled and received daily one dose of rosiglitazone (4mg) or pioglitazone (15mg). The mean follow-up duration was 25.39±9.66 months. We assessed insulin sensitivity using HOMA-IR and the short insulin tolerance test before and after TZDs treatment. Results: When we compared patients’ characteristics before and after TZDs treatment, the mean fasting glucose level was significantly decreased (183.27±55.04 to 137.35±36.42mg/dL, p<0.001) and the mean HbA1C level was significantly decreased (9.24±1.96 to 8.11±1.39%, p<0.001). Also, Kitt values were significantly increased (2.03±1.14 to 2.67±0.97%/min, p=0.003), whereas HOMA-IR was significantly decreased (2.98±0.68 to 1.04±0.24, p<0.05). When classifying insulin resistance by Kitt values, insulin resistant subjects’ values were increased (<2.5 %/min; 1.51±0.53%/min to 2.63±0.88, p<0.001), whereas the values decreased in insulin sensitive subjects (≥2.5%/min; 3.50± 0.75%/min to 2.75±1.12%/min, p=0.002). Conclusion: The glucose lowering effects of TZDs by improving insulin resistance could be determined by using Kitt. However, Kitt may be a beneficial tool to determine TZDs’ effects only when patients’ Kitt values are less than 2.5%/min.

참고문헌 (Reference)

1 Wallace TM, "Use and abuse of HOMA modeling" 27 : 1487-1495, 2004

2 Shimabukuro M, "Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats" 273 : 3547-3550, 1998

3 Park KS, "Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferatoractivatedreceptor-gamma" 83 : 2830-2835, 1998

4 Osei K, "Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone" 56 : 24-29, 2007

5 Gastaldelli A, "Thiazolidinediones improve beta-cell function in type 2 diabetic patients" 292 : E871-E883, 2007

6 Willson TM, "The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones" 39 : 665-668, 1996

7 Akinmokun A, "The short insulin tolerance test for determination of insulin sensitivity: a comparison with the euglycaemic clamp" 9 : 432-437, 1992

8 Morris AD, "The euglycaemic hyperinsulinaemic clamp: an evaluation of current methodology" 24 : 513-518, 1997

9 Mayerson AB, "The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes" 51 : 797-802, 2002

10 Yu JG, "The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects" 51 : 2968-2974, 2002

11 Gastaldelli A, "The effect of pioglitazone on the liver: role of adiponectin" 29 : 2275-2281, 2006

12 Garver WT, "The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus" 34 : 222-234, 1985

13 Grulet H, "Study of the rate of early glucose disappearance following insulin injection: insulin sensitivity index" 20 : 201-207, 1993

14 Park SW, "Short insulin tolerance test (SITT) for the determination of in vivo insulin sensitivity-a comparison with euglycemic clamp test" 22 : 199-208, 1998

15 Miyazaki Y, "Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients" 52 : 1943-1950, 2003

16 Hirst S, "Reproducibility of the short insulin tolerance test" 10 : 839-842, 1993

17 Robertson RP, "Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations" 90 : 320-325, 1992

18 Matsui J, "Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet" 53 : 2844-2854, 2004

19 Mudaliar S, "New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers" 52 : 239-257, 2001

20 Norris AW, "Muscle-specific PPARgamma-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones" 112 : 608-618, 2003

21 Derosa G, "Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome" 31 : 375-383, 2006

22 Derosa G, "Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial" 26 : 744-754, 2004

23 Inchiostro S, "Measurement of insulin sensitivity in Type 2 diabetes mellitus: comparison between KITT and HOMA-%S indices and evaluation of their relationship with the components of the insulin resistance syndrome" 22 : 39-44, 2005

24 Andrews WJ, "Insulin therapy in obese, noninsulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal" 33 : 634-642, 1984

25 Haffner SM, "Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascularrisk factors: the Insulin Resistance Atherosclerosis Study" 22 : 562-568, 1999

26 Howard G, "Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators" 93 : 1809-1817, 1996

27 Lempiäinen P, "Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men" 100 : 123-128, 1999

28 Miyazaki Y, "Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone" 24 : 710-719, 2001

29 Matthews DR, "Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man" 28 : 412-419, 1985

30 Bonora E, "Estimates of in vivo insulin action in man: comparison of insulin tolerance tests with euglycemic and hyperglycemic glucose clamp studies" 68 : 374-378, 1998

31 Boden G, "Effects of prolonged glucose infusion on insulin secretion, clearance, and action in normal subjects" 270 : E251-E258, 1996

32 Miyazaki Y, "Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes" 25 : 517-523, 2002

33 Radikova Z, "Assessment of insulin sensitivity/resistance in epidemiological studies" 37 : 189-194, 2003

34 Lehmann JM, "An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator- activated receptor gamma (PPAR gamma)" 270 : 12953-12956, 1995

35 Jones TA, "Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes" 5 : 163-170, 2003

36 Oberfield JL, "A peroxisome proliferatoractivated receptor gamma ligand inhibits adipocytedifferentiation" 96 : 6102-6106, 1999

37 Matsuhisa M, "A novel index of insulin resistance determined from the homeostasis model assessment index and adiponectin levels in Japanese subjects" 77 : 151-154, 2007